Case Study: Brugada’s - PowerPoint Presentation

Slide1

Case Study: Brugada’s Syndrome

Presented by: Fran Connolly

Slide2

Prime Care PhysiciansPreceptor: Dr. Jose David

Completed his residency at Albany Medical College in 1991

Started at Prime Care in 1997

Board Certified in Family Practice in 2003

Slide3

Patient & Encounter

M.E. is a 28 year old white male who presents in his primary care office for his annual physical exam on March 27, 2014.

Slide4

History of Present Illness

Initial visit: 2/5/2013

Pt c/o intermittent palpitations, felt his heart beating fast & irregular.

Episodes last 3-4 hours and stop spontaneously, usually happened at night.

Denied any C.P., syncope, SOB or dizziness.

At that visit

pt

received

Holter

monitor for 24 hour period which showed a 4 hour episode of paroxysmal atrial fibrillation that was symptomatic.

He stated most of the time events were triggered by large meals or alcohol.

Slide5

HPI (continued)

Pt was started on Toprol XL 50 mg PO daily & Aspirin 325 mg PO daily

Second visit: 3/8/2013

Pt states he has been having several episodes of a-fib over the past two weeks, lasts a couple of hours.

Changed medication to

Rythmol

225 mg PO BID

Slide6

HPI (continued)Third visit: 4/29/2013

f/u

pt

had AICD pacemaker placed on 4/21/2013.

Pt was jogging and had a

syncopal

episode, which he woke spontaneously from. Brought to the ER which his EKG revealed evidence of

Brugada syndrome, pacer placed.

D/C on

Sotalol

160 mg PO BID, Toprol XL 50 mg PO BID & ASA 81 mg PO daily.

Driving restriction placed for 6 months.

Slide7

HPI (continued)

Fourth visit: 7/9/2013

Pt continues with daily, intermittent episodes of a-fib

f/u and plan for radio frequency

ablasion

therapy

pt

started on Coumadin

Tests ordered prior to

ablasion

: TEE & CT chest

Ablasion

done on 9/12/2013 without incidence.

Visits up-to-date of 3/27/2014:

Med changes: Currently on Toprol XL 50 mg PO BID & ASA 81 mg PO daily.

Currently awaiting insurance approval for genetic testing regarding

Brugada’s

syndrome, denied the first time and there is an appeal in to the insurance company.

Slide8

Past Medical History

Mononucleosis, hospitalized for 2 days 6/2007.

Denies all other history including HTN, hyperlipidemia, stroke, lung disease, asthma, liver, kidney or gallbladder disease, cancer, diabetes, thyroid, hepatitis, TB or psychiatric disorders.

Denies any allergies to drugs, food, latex or environment.

Only medications are Toprol XL 50 mg PO BID & ASA 81 mg PO daily.

Slide9

Social History:Married with a 6 year old son.

Employed as an investment banker, financially secure.

Denies smoking or illicit drug use, states he rarely drinks alcohol or caffeine.

Exercises 5x week, 1

hr

day.

Family History:

Mother- DMII

Father- HTN

PGF- deceased @ 52 from MI

P (great) GF – deceased @ 60 from MI

Denies any other family history of cardiac issues

Slide10

Review of Systems:

General: Denies any fever, chills, fatigue, night sweats, appetite or weight changes.

Head: Denies any headache, dizziness, syncope or head injuries

Resp

: Denies any pain, dyspnea, orthopnea, wheezing, asthma, bronchitis, hemoptysis or SOB.

CV: Denies any C.P., murmurs, edema or palpitation @ this visit.

Neuro

: Denies any fainting, seizures, numbness, loss of sensation or tingling, tremors, speech difficulties or change in memory.

Slide11

Physical FindingsConstitutional: BP106/72, HR 68, RR 16, 98%

Ht

: 6’5”

Wt

: 212 lbs BMI: 26

General: Well nourished, well developed man. Alert & oriented x 3. Calm & cooperative. Appropriate mood & affect.

Skin: Pink, warm & dry. No

rashed or lesions. Scar over pacer placement on right chest wallResp

: Pt sitting upright,

resp

resting 16/min, regular & even. Chest expansion symmetric. No tenderness to palpation. Lungs clear throughout lung fields anterior & posterior. No

rales

, rhonchi or wheezes heard.

Slide12

Physical FindingsCV: S1S2 present in APETM w/ bell & diaphragm. Regular apical rate. No heaves or thrills. No murmurs, rubs, gallops or clicks. RRR. Apical pulse not palpable in 5

th

ICS @ LMC. Carotids 2+ equal

bilat

, internal jugular veins pulsation not present.

PV: Extremities pink, warm to touch. No edema. Pulses 2+ symmetric in radial &

dorsalis

pedals. No varicosities. Cap refill <3 seconds. No carotid bruit.

Slide13

Differential DiagnosisParoxysmal atrial fibrillation (427.31)

Cardiac

dysrhythmia (427.9)

Paroxysmal supraventricular

tachycardia (427.0)

Hyperthyroidism (242.9)

Brugada’s

syndrome (746.89)

Slide14

Diagnostic TestsEKG (2/5/13)- sinus rhythm. Rate 67. PR 188 QRS 118 QT 401. RSR Prime in lead V1 suggests right ventricular conduction delay. Poor R-wave progression.

Holter

(2/5/13)- SR w/ low grade atrial & ventricular

ectopy

& 4 hour episode of A-fib

ECHO (2/15/13)- Mild left ventricular hypertrophy. Dilated left atrium.

CT chest (8/21/13)- 4 pulmonary veins

TEE (8/21/13)- left ventricle is mildly dilated w/ normal systolic function (EF 60%), mild left atrial enlargement.

Slide15

Labs

Cholesterol 189, triglycerides 121, HDL 42, LDL 123

WBC 5.9, H/H 49/15, PLT 304

Glucose 110, K 4.0, Ca 8.7

BUN 133333, Cr 1.2

AST 18, ALT 21

TSH 2.253, T4 7.7, T3 34, & free TI 2.6

Slide16

DiagnosisAtrial Fibrillation (427.31)

Brugada’s

Syndrome (746.89)

However awaiting genetic testing to confirm 2

nd

dx.

Slide17

Brugada’s Syndrome

Potentially

life-threatening heart rhythm

disorder (Mayo Clinic, 2011).

This is a disorder characterized by an EKG pattern which has an incomplete right bundle branch block & ST-segment elevations in the anterior precordial leads (

Dizon

&

Zanif, 2014)This EKG abnormality is known as the type -1 Brugada syndrome EKG & combined with an absence of heart abnormalities will give the diagnosis.

This type of EKG is linked to increase risk for

ventricular

tachyarrhythmias

, cardiac arrest &

sudden

death. Shows familial aggregation.

(

Postema

, et al., 2009

)

Slide18

Slide19

Brugada’s SyndromeIt is recognized to cause sudden cardiac death at a relatively young age and most patients are

asymptomatic.

The typical patient

is a young

, male, and otherwise healthy, with normal general medical and cardiovascular physical examinations

.

Genetic testing can be done for mutation in

SCN5A.(Dizon & Zanif, 2014)

Slide20

Signs & SymptomsSyncope and cardiac arrest: in many cases, cardiac arrest occurs during sleep or rest

Nightmares or thrashing at night

Asymptomatic, but routine ECG shows ST-segment elevation in leads V1-V3

Associated atrial fibrillation (20%)

Fever: Often reported to trigger or exacerbate clinical manifestations

(

Dizon

& Zanif, 2014)

Slide21

Pathophysiology

A disease caused by an alteration in the transmembrane ion currents that together constitute the cardiac action potential.

In 10-30% of cases a mutation of the

SCN5A

gene, which encodes the cardiac voltage-gated sodium channel have been found.

This reduces the sodium current available during early repolarization & hence the ST elevations on EKG.

(

Dizon & Zanif, 2014)

Slide22

Slide23

EtiologySCN5A gene mutation

Many drugs can induce the type-1 EKG in

Brugada

syndrome & should be avoided:

Antiarrhythmics

-

Rythmol

, ProcainamidePsychotropics- amitriptyline, lithium, nortriptylineAnesthesia- bupivacaine, propofolTramadol, Benadryl, Reglan

(

Postema

, et al., 2009)

Slide24

Incidence

Most common in people from Asia. In Asia it is the most common cause of natural death in men younger than 50. approximately 30:100,000.

It is 8-10x more prevalent in men.

Most commonly affects men between 30-50 who are other-wise healthy.

The mean age of sudden death is 41 years old.

An

estimated 4% of

sudden deaths and at least 20% of sudden deaths in patients with structurally normal hearts are due to the

syndrome.

(

Dizon

& Zanif,2014)

Slide25

PlanInterventions:

The only treatment proven effective presently is the implantation of an

automatic implantable cardiac defibrillator

(AICD).

Slide26

Review of Literaturedescribed as a new clinical entity in 1992

The syndrome may also be unmasked or precipitated by a febrile state,

β-adrenergic

blockers, tricyclic

antidepressants

,

and

hypokalemia, as well as by alcohol and cocaine toxicity.In the case of M.E. he first started noticing his symptoms after consuming alcohol & he did not have a syncopal episode until he was placed on Rythmol.

Atrial fibrillation (AF) is reported in approximately 10%-20% of cases

Slide27

Review of Literature

The

appearance of a right bundle branch block (RBBB) morphology in

Brugada

patients may be due at least in part to early repolarization of RV

epicardium

.

Sudden death usually occur at rest and at night,M.E. typically felt his heart racing with palpitations at night when lying down.

The effectiveness of ICD

preventing

sudden cardiac death was 100% in a recent

trial

in which 258 patients

dx

with Brugada syndrome received an ICD.

(

Antzelevitch

&

Fish,

2006)

Slide28

Education

Family should be educated on CPR

There should be s/p AICD insertion education

The patient should be educated on medications that should be avoided

They should also make any & all provider aware of their diagnosis

They should be instructed to avoid alcohol, caffeine & cocaine

They can also have their family members tested for the gene as well.

Slide29

Follow -up

Currently he is seen every 3 months by cardiology.

He is seen in the PCP office every 6 months.

Awaiting the authorization from insurance for genetic testing to be done.

Was told to f/u sooner if having any s/s such as palpitations that do not subside after 2 hours.

Was told to go straight to the ER for any

syncopal

/near-syncopal episodes or if AICD fires.

Slide30

ReferencesAntzelevitch, C. & Fish, J.M. (2006). Therapy for the Brugada

syndrome.

Handb

Exp

Pharmacology

(171). 305-330. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474239/

Dizon, J.M. & Zanif, T.M. (2014) Brugada Syndrome. Retrieved from http://emedicine.medscape.com/article/163751-overview#aw2aab6b2b3aaMayo Clinic. (2011). Disease & conditions: Brugada syndrome. Retrieved from http://www.mayoclinic.org/diseases-conditions/brugada-syndrome/basics/definition/con-20034848

Postema

, P.G.,

Wolpert

, C., Amin, A.S.,

Probst

, V.,

Borggrefe, M., Roden, D.M.,…Wilde, A.A. ( 2009). Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (

www.brugadadrugs.org

).

Heart Rhythm 6

(9). 1335-41. DIO: 10.1016/j.hrthm.2009.07.002